Report
Eric Le Berrigaud

ASTRAZENECA: Strategic partnership with Daiichi Sankyo in Her2-positive cancers | NEUTRAL | 6220p

ASTRAZENECA - NEUTRAL | 6220p(-3%)
Strategic partnership with Daiichi Sankyo in Her2-positive cancers

AstraZeneca gets access to an interesting asset
A rich deal funded by an equity placement
We expect small EPS dilution in 2019 and 2020 and accretion after
Underlying
AstraZeneca PLC

AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Eric Le Berrigaud

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch